Cervical Cancer Diagnostic Global Market Report 2022: Rising Prevalence of Cervical Cancer Driving Growth - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--Sep 28, 2022--

The "Cervical Cancer Diagnostic Market Size, Share, Trends, By Test Type, By End User, By Therapy, and By Region Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.

The global cervical cancer diagnostics market size is expected to reach USD 9,180.63 Million in 2030 and register a revenue CAGR of 5.0% over the forecast period, according to latest report. The growth of this market is driven by the rising prevalence of cervical cancer and government initiatives for early detection of cervical cancer. According to the National Cancer Institute, in 2019, an estimated 13,170 women in the United States will be diagnosed with cervical cancer.

Cervical cancer is caused by human papillomavirus (HPV) infection. HPV is a sexually transmitted infection that can be passed from one person to another through skin-to-skin contact. There are more than 150 types of HPV, and some of these types can lead to cancer.

The most common symptom of cervical cancer is abnormal bleeding from the vagina. Other symptoms include pain during sex, vaginal discharge, and pelvic pain. Cervical cancer is diagnosed through Pap smear test, which is a screening test to detect abnormal cells in the cervix. Treatment for cervical cancer depends on the stage of cancer. The most common treatments are surgery, radiation therapy, and chemotherapy.

The diagnostic test used for cervical cancer is a simple process in which a sample of cervical tissue is taken and examined for the presence of cancer cells. The most common diagnostic tests used for cervical cancer are Pap smear, HPV DNA test, and colposcopy.

Private healthcare companies are focusing on developing new and improved cancer diagnostic technologies to cater to the needs of the rising patient population. For instance, in October 2019, Abbott introduced a new next-generation sequencing-based test for advanced cervical cancer. The test is designed to help clinicians identify patients who may benefit from targeted therapies.

Market Dynamics

Market Drivers

• Rising Prevalence of Cervical Cancer
• Growing Awareness About Cancer Screening
• Technological Advancements in Cancer Diagnosis Equipment
• Increasing Accuracy of Pap Smear Tests

Market Restraints

• Barriers or Lack of Knowledge About Risk Factors for Cervical Cancer
• High Cost of Manufacturing Equipment

Market Segmentation

Test Type Outlook (Revenue, USD Billion; 2019-2030)

• Pap Smear Tests
• Colposcopy
• HPV Testing
• Biopsy and Endocervical curettage
• Others

End-use Outlook (Revenue, USD Billion; 2019-2030)

• Hospitals and Clinics
• Laboratories
• Diagnosing Centers
• Others

Therapy Outlook (Revenue, USD Billion; 2019-2030)

• Surgery
• Radiation Therapy
• Chemotherapy
• Targeted Therapy

Regional Outlook (Revenue, USD Billion; 2019-2030)

• North America
• U.S.
• Canada
• Mexico
• Europe
• Germany
• U.K.
• France
• Italy
• Spain
• Sweden
• BENELUX
• Rest of Europe
• Asia-Pacific
• China
• India
• Japan
• South Korea
• Rest of APAC
• Latin America
• Brazil
• Rest of LATAM
• Middle East & Africa
• Saudi Arabia
• UAE
• South Africa
• Israel
• Rest of MEA

Key Topics Covered:

Chapter 1. Market Synopsis

Chapter 2. Executive Summary

Chapter 3. Indicative Metrics

Chapter 4. Cervical Cancer Diagnostic Market Segmentation & Impact Analysis

Chapter 5. Cervical Cancer Diagnostic Market By Test Type Insights & Trends

Chapter 6. Cervical Cancer Diagnostic Market by End-Use Insights & Trends

Chapter 7. Cervical Cancer Diagnostic Market By Therapy Insights & Trends

Chapter 8. Cervical Cancer Diagnostic Market Regional Outlook

Chapter 9. Competitive Landscape

Chapter 10. Company Profiles

Companies Mentioned

• Abbott Laboratories Ltd.
• Becton Dickinson and Company
• F. Hoffmann-La Roche Ltd.
• Guided Therapeutics Inc.
• Hologic Inc.
• Qiagen N.V.
• Quest Diagnostics Inc.
• CooperSurgical Inc.
• Arbor Vita Corporation.

For more information about this report visit https://www.researchandmarkets.com/r/kwqnvl

View source version on businesswire.com:https://www.businesswire.com/news/home/20220928005648/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

KEYWORD:

INDUSTRY KEYWORD: BIOTECHNOLOGY HEALTH ONCOLOGY

SOURCE: Research and Markets

Copyright Business Wire 2022.